ELI LILLY AND COMPANY (NYSE: LLY)

ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: 6 hari lalu, 1:13PM

1,038.40

5.43 (0.53%)

Tambah ke senarai pantauan

Penutupan Terdahulu	1,032.97
Buka	1,024.43
Jumlah Dagangan	2,849,285
Purata Dagangan (3B)	3,523,543
Modal Pasaran	930,880,749,568

Harga / Pendapatan (P/E TTM)	50.75
Harga / Pendapatan (P/E Ke hadapan)	31.75
Harga / Jualan (P/S)	15.74
Harga / Buku (P/B)	39.06

Julat 52 Minggu	623.78 (-39%) — 1,133.95 (9%)
Tarikh Pendapatan	4 Feb 2026
Hasil Dividen (DY TTM)	0.14%

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Drug Manufacturers - General (US)	Menaik	Bercampur
	Drug Manufacturers - General (Global)	Menaik	Bercampur
Stok	Eli Lilly and Company	Menaik	Menaik

AISkor Stockmoo

1.1

Konsensus Penganalisis	1.5
Aktiviti Orang Dalam	3.0
Volatiliti Harga	-0.5
Purata Bergerak Teknikal	1.0
Osilator Teknikal	0.5
Purata	1.10

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
LLY	931 B	0.14%	50.75	39.06
NVO	277 B	1.77%	17.05	10.49
NVS	272 B	3.27%	19.43	6.21
JNJ	530 B	0.56%	19.96	6.64
ABBV	394 B	1.47%	169.09	50.46
MRK	273 B	0.74%	14.44	5.24

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor	Healthcare
Industri	Drug Manufacturers - General
Gaya Pelaburan	Large Growth
% Dimiliki oleh Orang Dalam	0.16%
% Dimiliki oleh Institusi	83.96%

Pemilikan

Nama	Tarikh	Syer Dipegang
Lilly Endowment Inc	30 Sep 2025	95,492,993

Julat 52 Minggu	623.78 (-39%) — 1,133.95 (9%)
Julat Harga Sasaran	950.00 (-8%) — 1,500.00 (-99%)
Tinggi	1,500.00 (Citigroup, 44.45%)	Beli
Median	1,200.00 (15.56%)
Rendah	950.00 (Freedom Capital Markets, -8.51%)	Pegang
Purata	1,195.39 (15.12%)
Jumlah	12 Beli, 1 Pegang
Harga Purata @ Panggilan	1,019.51

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
Guggenheim	20 Jan 2026	1,161.00 (11.81%)	Beli	1,041.29
UBS	07 Jan 2026	1,250.00 (20.38%)	Beli	1,108.09
UBS	07 Nov 2025	1,080.00 (4.01%)	Beli	924.37
B of A Securities	15 Dec 2025	1,268.00 (22.11%)	Beli	1,062.19
Wells Fargo	10 Dec 2025	1,200.00 (15.56%)	Beli	993.64
BMO Capital	04 Dec 2025	1,200.00 (15.56%)	Beli	1,014.49
BMO Capital	06 Nov 2025	1,100.00 (5.93%)	Beli	937.44
Bernstein	24 Nov 2025	1,300.00 (25.19%)	Beli	1,070.16
Morgan Stanley	24 Nov 2025	1,290.00 (24.23%)	Beli	1,070.16
Morgan Stanley	13 Nov 2025	1,171.00 (12.77%)	Beli	1,022.87
Truist Securities	19 Nov 2025	1,182.00 (13.83%)	Beli	1,049.60
JP Morgan	18 Nov 2025	1,150.00 (10.75%)	Beli	1,030.05
Citigroup	12 Nov 2025	1,500.00 (44.45%)	Beli	1,017.78
Freedom Capital Markets	10 Nov 2025	950.00 (-8.51%)	Pegang	966.64
Leerink Partners	10 Nov 2025	1,104.00 (6.32%)	Beli	966.64
Cantor Fitzgerald	31 Oct 2025	985.00 (-5.14%)	Beli	862.86
Papar semua

Nama	Purata Belian ($)	Purata Jualan ($)	Jumlah Net	Jumlah Nilai Bersih ($)
ALVAREZ RALPH	1,041.29	-	12	12,495
FYRWALD J ERIK	1,041.29	-	10	10,413
LUCIANO JUAN R	1,041.29	-	15	15,619
SULZBERGER GABRIELLE	1,041.29	-	5	5,206
Jumlah Keseluruhan Kuantiti Bersih				42
Jumlah Keseluruhan Nilai Bersih ($)				43,734
Purata Pembelian Keseluruhan ($)				1,041.29
Purata Jualan Keseluruhan ($)				-

Nama	Pemegang	Tarikh	Jenis	Kuantiti	Harga	Nilai ($)
ALVAREZ RALPH	Pengarah	20 Jan 2026	Diperolehi (+)	12	1,041.29	12,495
FYRWALD J ERIK	Pengarah	20 Jan 2026	Diperolehi (+)	10	1,041.29	10,413
LUCIANO JUAN R	Pengarah	20 Jan 2026	Diperolehi (+)	15	1,041.29	15,619
SULZBERGER GABRIELLE	Pengarah	20 Jan 2026	Diperolehi (+)	5	1,041.29	5,206

Tarikh	Jenis	Butiran
23 Jan 2026	CNBC	What obesity drugmakers see next in the market: More pills, easier access and drug combinations
21 Jan 2026	Pengumuman	Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
20 Jan 2026	Pengumuman	Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
16 Jan 2026	CNBC	Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026	CNBC	2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026	CNBC	Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
09 Jan 2026	Pengumuman	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
08 Jan 2026	Pengumuman	Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
07 Jan 2026	Pengumuman	Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
05 Jan 2026	CNBC	First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
22 Dec 2025	CNBC	FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	Pengumuman	Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
18 Dec 2025	CNBC	Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
16 Dec 2025	Pengumuman	Lilly to participate in J.P. Morgan Healthcare Conference
12 Dec 2025	Pengumuman	Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
11 Dec 2025	Pengumuman	Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
11 Dec 2025	CNBC	Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
09 Dec 2025	Pengumuman	Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
09 Dec 2025	Pengumuman	Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
09 Dec 2025	Pengumuman	Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
09 Dec 2025	CNBC	Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
08 Dec 2025	Pengumuman	Carolyn Bertozzi returns to Lilly board of directors
08 Dec 2025	Pengumuman	Lilly declares first-quarter 2026 dividend
07 Dec 2025	Pengumuman	Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
03 Dec 2025	Pengumuman	U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
01 Dec 2025	CNBC	Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
24 Nov 2025	Pengumuman	Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
24 Nov 2025	CNBC	Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
24 Nov 2025	Pengumuman	Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
19 Nov 2025	Pengumuman	Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
18 Nov 2025	Pengumuman	Lilly to participate in Citi's 2025 Global Healthcare Conference
17 Nov 2025	CNBC	Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
10 Nov 2025	Pengumuman	Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
07 Nov 2025	CNBC	Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025	CNBC	Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025	CNBC	Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
06 Nov 2025	CNBC	Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025	Pengumuman	Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
06 Nov 2025	Pengumuman	Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
06 Nov 2025	Pengumuman	Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
04 Nov 2025	CNBC	Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
03 Nov 2025	CNBC	Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
03 Nov 2025	Pengumuman	Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
02 Nov 2025	CNBC	Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025	CNBC	Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
30 Oct 2025	Pengumuman	Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
29 Oct 2025	CNBC	Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
29 Oct 2025	Pengumuman	LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
29 Oct 2025	Pengumuman	Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
28 Oct 2025	Pengumuman	Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
28 Oct 2025	Pengumuman	Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
28 Oct 2025	CNBC	Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
27 Oct 2025	Pengumuman	Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
27 Oct 2025	Pengumuman	Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
27 Oct 2025	Pengumuman	Lilly declares fourth-quarter 2025 dividend
27 Oct 2025	Pengumuman	Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
Papar semua

Hasil Dividen (DY TTM)	0.14%
Purata Hasil Dividen 5T	0.78%
Nisbah Pembayaran	43.94%

Tarikh EX	Tarikh Pengumuman	Tarikh Pembayaran	Perincian
14 Feb 2025	09 Dec 2024	10 Mar 2025	1.5 Tunai
15 Nov 2024	28 Oct 2024	10 Dec 2024	1.3 Tunai
15 Aug 2024	24 Jun 2024	10 Sep 2024	1.3 Tunai
15 May 2024	06 May 2024	10 Jun 2024	1.3 Tunai
14 Feb 2024	08 Dec 2023	08 Mar 2024	1.3 Tunai
14 Nov 2023	01 Nov 2023	08 Dec 2023	1.13 Tunai
14 Aug 2023	26 Jun 2023	08 Sep 2023	1.13 Tunai
12 May 2023	01 May 2023	09 Jun 2023	1.13 Tunai
14 Feb 2023	12 Dec 2022	10 Mar 2023	1.13 Tunai
14 Nov 2022	17 Oct 2022	09 Dec 2022	0.98 Tunai
12 Aug 2022	27 Jun 2022	09 Sep 2022	0.98 Tunai
13 May 2022	02 May 2022	10 Jun 2022	0.98 Tunai
14 Feb 2022	13 Dec 2021	10 Mar 2022	0.98 Tunai
12 Nov 2021	18 Oct 2021	10 Dec 2021	0.85 Tunai
12 Aug 2021	29 Jun 2021	10 Sep 2021	0.85 Tunai
13 May 2021	03 May 2021	10 Jun 2021	0.85 Tunai
11 Feb 2021	14 Dec 2020	10 Mar 2021	0.85 Tunai
12 Nov 2020	19 Oct 2020	10 Dec 2020	0.74 Tunai
13 Aug 2020	15 Jul 2020	10 Sep 2020	0.74 Tunai
14 May 2020	04 May 2020	10 Jun 2020	0.74 Tunai
13 Feb 2020	16 Dec 2019	10 Mar 2020	0.74 Tunai
14 Nov 2019	22 Oct 2019	10 Dec 2019	0.645 Tunai
14 Aug 2019	20 Jun 2019	10 Sep 2019	0.645 Tunai
16 May 2019	07 May 2019	10 Jun 2019	0.645 Tunai
14 Feb 2019	19 Dec 2018	08 Mar 2019	0.645 Tunai
14 Nov 2018	16 Oct 2018	10 Dec 2018	0.5625 Tunai
14 Aug 2018	19 Jun 2018	10 Sep 2018	0.5625 Tunai
16 May 2018	07 May 2018	08 Jun 2018	0.5625 Tunai
14 Feb 2018	11 Dec 2017	09 Mar 2018	0.5625 Tunai
14 Nov 2017	16 Oct 2017	08 Dec 2017	0.52 Tunai
11 Aug 2017	19 Jun 2017	08 Sep 2017	0.52 Tunai
11 May 2017	01 May 2017	09 Jun 2017	0.52 Tunai
13 Feb 2017	12 Dec 2016	10 Mar 2017	0.52 Tunai
10 Nov 2016	17 Oct 2016	09 Dec 2016	0.51 Tunai
11 Aug 2016	20 Jun 2016	09 Sep 2016	0.51 Tunai
11 May 2016	02 May 2016	10 Jun 2016	0.51 Tunai
10 Feb 2016	08 Dec 2015	10 Mar 2016	0.51 Tunai
10 Nov 2015	19 Oct 2015	10 Dec 2015	0.5 Tunai
12 Aug 2015	15 Jun 2015	10 Sep 2015	0.5 Tunai
14 May 2015	04 May 2015	10 Jun 2015	0.5 Tunai
11 Feb 2015	15 Dec 2014	10 Mar 2015	0.5 Tunai
12 Nov 2014	20 Oct 2014	10 Dec 2014	0.49 Tunai
13 Aug 2014	16 Jun 2014	10 Sep 2014	0.49 Tunai
13 May 2014	05 May 2014	10 Jun 2014	0.49 Tunai
12 Feb 2014	16 Dec 2013	10 Mar 2014	0.49 Tunai
13 Nov 2013	21 Oct 2013	10 Dec 2013	0.49 Tunai
13 Aug 2013	18 Jun 2013	10 Sep 2013	0.49 Tunai
14 May 2013	03 May 2013	10 Jun 2013	0.49 Tunai
13 Feb 2013	17 Dec 2012	08 Mar 2013	0.49 Tunai
13 Nov 2012	15 Oct 2012	10 Dec 2012	0.49 Tunai
13 Aug 2012	19 Jun 2012	10 Sep 2012	0.49 Tunai
13 Feb 2012	12 Dec 2011	09 Mar 2012	0.49 Tunai
10 Nov 2011	17 Oct 2011	09 Dec 2011	0.49 Tunai
11 Aug 2011	20 Jun 2011	09 Sep 2011	0.49 Tunai
11 May 2011	18 Apr 2011	10 Jun 2011	0.49 Tunai
11 Feb 2011	13 Dec 2010	10 Mar 2011	0.49 Tunai
10 Nov 2010	18 Oct 2010	10 Dec 2010	0.49 Tunai
11 Aug 2010	21 Jun 2010	10 Sep 2010	0.49 Tunai
12 May 2010	19 Apr 2010	10 Jun 2010	0.49 Tunai
10 Feb 2010	14 Dec 2009	10 Mar 2010	0.49 Tunai
10 Nov 2009	19 Oct 2009	10 Dec 2009	0.49 Tunai
12 Aug 2009	22 Jun 2009	10 Sep 2009	0.49 Tunai
13 May 2009	20 Apr 2009	10 Jun 2009	0.49 Tunai
11 Feb 2009	15 Dec 2008	10 Mar 2009	0.49 Tunai
12 Nov 2008	20 Oct 2008	10 Dec 2008	0.47 Tunai
13 Aug 2008	20 Jun 2008	10 Sep 2008	0.47 Tunai
13 Feb 2008	17 Dec 2007	10 Mar 2008	0.47 Tunai
13 Nov 2007	15 Oct 2007	10 Dec 2007	0.425 Tunai
13 Aug 2007	21 Jun 2007	10 Sep 2007	0.425 Tunai
11 May 2007	16 Apr 2007	08 Jun 2007	0.425 Tunai
13 Feb 2007	18 Dec 2006	09 Mar 2007	0.425 Tunai
13 Nov 2006	16 Oct 2006	08 Dec 2006	0.4 Tunai
11 Aug 2006	26 Jun 2006	08 Sep 2006	0.4 Tunai
11 May 2006	24 Apr 2006	09 Jun 2006	0.4 Tunai
13 Feb 2006	19 Dec 2005	10 Mar 2006	0.4 Tunai
10 Nov 2005	17 Oct 2005	09 Dec 2005	0.38 Tunai
11 Aug 2005	24 Jun 2005	09 Sep 2005	0.38 Tunai
11 May 2005	18 Apr 2005	10 Jun 2005	0.38 Tunai
11 Feb 2005	20 Dec 2004	10 Mar 2005	0.38 Tunai
10 Nov 2004	18 Oct 2004	10 Dec 2004	0.355 Tunai
11 Aug 2004	28 Jun 2004	10 Sep 2004	0.355 Tunai
12 May 2004	19 Apr 2004	10 Jun 2004	0.355 Tunai
11 Feb 2004	15 Dec 2003	10 Mar 2004	0.355 Tunai
12 Nov 2003	20 Oct 2003	10 Dec 2003	0.335 Tunai
13 Aug 2003	23 Jun 2003	10 Sep 2003	0.335 Tunai
13 May 2003	28 Apr 2003	10 Jun 2003	0.335 Tunai
12 Feb 2003	16 Dec 2002	10 Mar 2003	0.335 Tunai
13 Nov 2002	21 Oct 2002	10 Dec 2002	0.31 Tunai
13 Aug 2002	24 Jun 2002	10 Sep 2002	0.31 Tunai
13 May 2002	15 Apr 2002	10 Jun 2002	0.31 Tunai
13 Feb 2002	17 Dec 2001	08 Mar 2002	0.31 Tunai
13 Nov 2001	15 Oct 2001	10 Dec 2001	0.28 Tunai
13 Aug 2001	25 Jun 2001	10 Sep 2001	0.28 Tunai
11 May 2001	16 Apr 2001	11 Jun 2001	0.28 Tunai
13 Feb 2001	18 Dec 2000	09 Mar 2001	0.28 Tunai
13 Nov 2000	16 Oct 2000	11 Dec 2000	0.26 Tunai
11 Aug 2000	26 Jun 2000	11 Sep 2000	0.26 Tunai
11 May 2000	17 Apr 2000	09 Jun 2000	0.26 Tunai
11 Feb 2000	20 Dec 1999	10 Mar 2000	0.26 Tunai
10 Nov 1999	18 Oct 1999	10 Dec 1999	0.23 Tunai
11 Aug 1999	19 Jul 1999	10 Sep 1999	0.23 Tunai
12 May 1999	19 Apr 1999	10 Jun 1999	0.23 Tunai
10 Feb 1999	21 Dec 1998	10 Mar 1999	0.23 Tunai
10 Nov 1998	20 Oct 1998	10 Dec 1998	0.2 Tunai
12 Aug 1998	20 Jul 1998	10 Sep 1998	0.2 Tunai
13 May 1998	20 Apr 1998	10 Jun 1998	0.2 Tunai
11 Feb 1998	15 Dec 1997	10 Mar 1998	0.2 Tunai
12 Nov 1997	15 Sep 1997	10 Dec 1997	0.2 Tunai
13 Aug 1997	21 Jul 1997	10 Sep 1997	0.36 Tunai
13 May 1997	21 Apr 1997	10 Jun 1997	0.36 Tunai
12 Feb 1997	16 Dec 1996	10 Mar 1997	0.36 Tunai
13 Nov 1996	21 Oct 1996	10 Dec 1996	0.3425 Tunai
13 Aug 1996	15 Jul 1996	10 Sep 1996	0.3425 Tunai
13 May 1996	15 Apr 1996	10 Jun 1996	0.3425 Tunai
13 Feb 1996	18 Dec 1995	11 Mar 1996	0.3425 Tunai
13 Nov 1995	17 Oct 1995	11 Dec 1995	0.685 Tunai
11 Aug 1995	17 Jul 1995	11 Sep 1995	0.645 Tunai
09 May 1995	17 Apr 1995	12 Jun 1995	0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun	Dividen Tahunan ($)	Kekerapan/Tahun	Hasil %
2025	1.50	1	0.14
2024	5.20	4	0.67
2023	4.52	4	0.78
2022	3.92	4	1.07
2021	3.40	4	1.23
2020	2.96	4	1.75
2019	2.58	4	1.96
2018	2.25	4	1.94
2017	2.08	4	2.46
2016	2.04	4	2.77
2015	2.00	4	2.37
2014	1.96	4	2.84
2013	1.96	4	3.84
2012	1.47	3	2.98
2011	1.96	4	4.72
2010	1.96	4	5.59
2009	1.96	4	5.49
2008	1.41	3	3.50
2007	1.70	4	3.18
2006	1.60	4	3.07
2005	1.52	4	2.69
2004	1.42	4	2.50
2003	1.34	4	1.91
2002	1.24	4	1.95
2001	1.12	4	1.43
2000	1.04	4	1.12
1999	0.920	4	1.38
1998	0.800	4	0.90
1997	1.28	4	1.84
1996	1.37	4	3.75
1995	1.98	3	7.02
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2026	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	22.67%
Margin Operasi (TTM)	42.49%
EPS Cair (TTM)	12.27
Pertumbuhan Hasil Suku Tahunan (YOY)	45.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY)	23.00%

Jumlah Hutang/Ekuiti (D/E MRQ)	243.61%
Nisbah Semasa (MRQ)	1.37
Aliran Tunai Operasi (OCF TTM)	9.32 B
Aliran Tunai Bebas Leveraj (LFCF TTM)	-1.82 B

Pulangan Atas Aset (ROA TTM)	16.45%
Pulangan Atas Ekuiti (ROE TTM)	77.28%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)